William Blair
About William Blair
William Blair is a global financial services firm specializing in investment banking, investment management, and private wealth management. The firm provides advisory services, strategies, and solutions to meet clients’ evolving needs across markets. It emphasizes thought leadership and research through its Think/Insights channels, delivering market perspectives and investment ideas to institutional, corporate, and private clients. Headquartered in the United States, William Blair operates with a multinational footprint and a focus on client-centric financial guidance.
Recent News
5 FDA Decisions to Watch in the First Quarter of 2026
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
FDA Grants First Gene‑Therapy Approval for Rare Pediatric Immune Disorder LAD‑I
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
How Non-Payments Became Big Business at Visa and Mastercard
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
What FIS Has Planned After the Global Payment Deals
Asset Allocation Still Dominates Outcomes as Investors Navigate New Inflation Era, Says William Blair
Barclays Reiterates Overweight on BridgeBio Stock, Cites Attruby Strength
William Blair Downgrades Adobe (ADBE) to Market Perform, Lowers PT
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
Circle’s USDC Keeps Climbing; William Blair Reiterates Outperform After 3Q Results
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
5 Questions Facing Biopharma in 2026
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Research Analysts Set Expectations for CSL FY2027 Earnings
Colliers Buys Ayesa, Which Bought ADP Just 12 Months Ago
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
Amex CEO: 10% Rate Cap Would Create 'Downward Spiral'
Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
Mattress Firm Parent Somnigroup to Buy One of Its Suppliers for $2.5B
Visa Doles Out Stablecoin Advice
Real Estate Stock Prices Have Taken a Big Hit in the Past Year
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
Industry Leaders Continue to Weigh in on Zillow Preview
Viasat Sees Orbital Data Center Partnership Opportunity
Investors Should Buy the Dip in Coinbase and Circle, Says William Blair
William Blair Reiterates Outperform on ARS Pharma Stock After FDA Label Update
HawkEye 360 Files S‑1 for NYSE Debut, Ticker HAWK Set for First U.S. Satellite‑Data IPO This Week
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
14 Most Undervalued Cybersecurity Stocks to Invest In
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
